Veraxa Biotech Holding AG (VRXAW) Cash & Equivalents (2024 - 2025)
Veraxa Biotech Holding AG (VRXAW) posted quarterly Cash & Equivalents of $126368.1 for Q4 2025, down 97.94% year-over-year from $6.1 million in Q4 2024, and down 97.94% quarter-over-quarter from $6.1 million in Q4 2024.
Veraxa Biotech Holding AG (VRXAW) Cash & Equivalents (2024 - 2025) Analysis & Trends
Veraxa Biotech Holding AG (VRXAW) has reported Cash & Equivalents for 2 consecutive years, with $126368.1 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash & Equivalents fell 97.94% year-over-year to $126368.1; the TTM figure through Dec 2025 stood at $126368.1 (down 97.94% YoY), while the FY2025 annual figure was $126368.1, down 97.94% from the prior year.
- Cash & Equivalents retreated to $126368.1 in Q4 2025 per VRXAW's latest filing, from $6.1 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $6.1 million in Q4 2024 and bottomed at $126368.1 in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 126,368.15 |
| Dec 31, 2024 | 6.12 Mn |